Share
Share today's newsletter with a colleague and get credit if they sign up for SmartBrief.
Referral Count:
 
0

Story being shared
AiCuris licenses HCMV portfolio to Merck
AiCuris granted Merck & Co. global rights to develop and market its portfolio of drug candidates targeting the human cytomegalovirus. The deal covers AiCuris' drug candidate letermovir, or AIC246, which has been evaluated in a midstage trial for prevention and treatment of CMV infection in transplant patients. AiCuris will receive about $142 million upfront and as much as $433 million in milestone fees plus sales royalties. "This portfolio complements Merck's broad antiviral portfolio," Merck Senior Vice President Dr. Roger Pomerantz said.

Or we can send an email on your behalf
You must submit valid email addresses only. Use of email addresses is subject to terms of SmartBrief's privacy policy .